Media headlines about OpGen (NASDAQ:OPGN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OpGen earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 46.4749380854252 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

Several research analysts have issued reports on OPGN shares. Zacks Investment Research cut OpGen from a “buy” rating to a “hold” rating in a research report on Saturday, August 26th. HC Wainwright set a $1.00 price objective on OpGen and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Finally, Dawson James reiterated a “buy” rating on shares of OpGen in a research report on Monday, June 19th.

OpGen (OPGN) traded up 1.6897% during mid-day trading on Friday, reaching $0.2949. The company’s stock had a trading volume of 2,222,257 shares. The company’s market capitalization is $15.20 million. OpGen has a 1-year low of $0.25 and a 1-year high of $3.10. The firm has a 50 day moving average price of $0.30 and a 200-day moving average price of $0.30.

In other news, Chairman Jven Capital, Llc acquired 1,875,000 shares of the company’s stock in a transaction dated Tuesday, July 18th. The shares were bought at an average price of $0.40 per share, with a total value of $750,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Timothy C. Dec acquired 65,000 shares of the company’s stock in a transaction dated Tuesday, July 18th. The stock was purchased at an average cost of $0.40 per share, for a total transaction of $26,000.00. Following the purchase, the chief financial officer now directly owns 118,966 shares in the company, valued at approximately $47,586.40. The disclosure for this purchase can be found here. 31.83% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “OpGen (OPGN) Getting Somewhat Favorable Press Coverage, Report Shows” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Insider Buying and Selling by Quarter for OpGen (NASDAQ:OPGN)

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.